NASDAQ:ATTO Attovia Therapeutics Q2 2026 Earnings Report $23.13 +0.91 (+4.10%) Closing price 04:00 PM EasternExtended Trading$23.20 +0.07 (+0.30%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Attovia Therapeutics EPS ResultsActual EPS-$4.88Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAttovia Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAttovia Therapeutics Announcement DetailsQuarterQ2 2026Date9/2/2026TimeAfter Market ClosesConference Call DateWednesday, September 2, 2026Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Attovia Therapeutics Earnings HeadlinesAttovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update3 hours ago | globenewswire.comLifeSci Capital initiates coverage of Attovia Therapeutics (ATTO) with outperform recommendation3 hours ago | msn.com#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"The federal government is throwing its full support behind a new class of AI technology, in what's being called the biggest push since the Apollo moon landing. This AI reportedly works 10,000 times faster than human PhDs and could eventually be worth 500 times more than ChatGPT. Elon Musk has called the underlying tech the most disruptive force in history.September 2 at 1:00 AM | Stansberry Research (Ad)Lifesci Capital Initiates Coverage on Attovia Therapeutics (NASDAQ:ATTO)September 2 at 2:26 AM | americanbankingnews.comCitigroup Initiates Coverage on Attovia Therapeutics (NASDAQ:ATTO)September 2 at 1:50 AM | americanbankingnews.comLeerink Partners Begins Coverage on Attovia Therapeutics (NASDAQ:ATTO)September 2 at 1:50 AM | americanbankingnews.comSee More Attovia Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Attovia Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Attovia Therapeutics and other key companies, straight to your email. Email Address About Attovia TherapeuticsAttovia Therapeutics (NASDAQ:ATTO) (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs. Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways. Its pipeline is centered on potential treatments for conditions involving dysregulated immune responses, although many of its programs remain in development and are subject to clinical and regulatory evaluation. As a development-stage biotechnology company, Attovia’s activities primarily involve research, preclinical studies, clinical trials and the advancement of its proprietary therapeutic pipeline. Publicly available information provides limited detail about its commercial operations, geographic reach and leadership beyond its focus on developing innovative treatments for inflammatory diseases.View Attovia Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestLilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond ObesityWendy’s Rally Fades After Trian Steps Back: Was It Ever Real?From High Dividend Growth to High Yield, These 3 Stocks Just Boosted Dividend PayoutsJ.M. Smucker Stock's Rally Has More Than Tariffs Behind ItUlta Beauty’s Earnings Beat Was Stronger Than the Stock’s ReactionNVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat Upcoming Earnings Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
